2-N-benzyl-9-ethyl-8-pyrazol-1-ylpurine-2,6-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-N-benzyl-9-ethyl-8-pyrazol-1-ylpurine-2,6-diamine
• 化学式: C₁₇H₁₈N₈
• 分子量: 334.4
• InChiKey: PKGIWKARLRXHQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  99.5
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• A3 ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Zablocki Jeff

  公开号：US20090099212A1

  公开（公告）日：2009-04-16

  Disclosed are novel methods of antagonizing the A 3 adenosine receptor in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the formula: wherein R is hydrogen or acyl; R 1 is hydrogen, halo, optionally substituted C 1-4 alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is optionally substituted C 1-4 alkyl; Y is C 1-4 alkylene; and Z is phenyl, optionally substituted with halo, optionally substituted C 1-4 alkyl, or C 1-4 alkoxy. The A 3 adenosine receptors may be antagonized in order to treat a disease state is chosen from renal failure, nephritis, hypertension, oedemas, Alzheimers disease, stress, depression, cardiac arrhythmia, restoration of cardiac function, asthma, respiratory disorders, ischemia-induced injury of the brain, heart and kidney, and diarrhea. Preferred compounds selectively antagonize A 3 adenosine receptors over A 1 adenosine receptors, A 2A adenosine receptors and A 2B adenosine receptors.

  本发明涉及一种在哺乳动物中拮抗A3腺苷受体的新方法，包括向需要治疗的哺乳动物中给予化合物的治疗有效剂量，该化合物的结构式为：其中R为氢或酰基；R1为氢、卤素、可选取代的C1-4烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环基；R2为可选取代的C1-4烷基；Y为C1-4烷基；Z为苯基，可选取代卤素、可选取代的C1-4烷基或C1-4烷氧基。可以拮抗A3腺苷受体以治疗肾功能衰竭、肾炎、高血压、水肿、阿尔茨海默病、压力、抑郁症、心律失常、恢复心脏功能、哮喘、呼吸系统疾病、缺血性脑、心脏和肾脏损伤以及腹泻等疾病状态。优选的化合物选择性地拮抗A3腺苷受体而不是A1腺苷受体、A2A腺苷受体和A2B腺苷受体。
• A2B adenosine receptor antagonists
  申请人：——

  公开号：US20030064999A1

  公开（公告）日：2003-04-03

  Disclosed are novel compounds that are A 2B adenosine receptor antagonists, useful for treating various disease states, in particular asthma and diarrhea.

  本发明涉及新型化合物，其为A2B腺苷受体拮抗剂，可用于治疗各种疾病状态，特别是哮喘和腹泻。
• Methods of labelling polynucleotides with dibenzorhodamine dyes
  申请人：Applera Corporation

  公开号：US20040072209A1

  公开（公告）日：2004-04-15

  Dibenzorhodamine compounds having the structure 1 are disclosed, including nitrogen- and aryl-substituted forms thereof. In addition, two intermediates useful for synthesizing such compounds are disclosed, a first intermediate having the structure 2 including nitrogen- and aryl-substituted forms thereof, and a second intermediate having the structure 3 including nitrogen- and aryl-substituted forms thereof, wherein substituents at positions C-14 to C18 taken separately are selected from the group consisting of hydrogen, chlorine, fluorine, lower alkyl, carboxylic acid, sulfonic acid, —CH 2 OH, alkoxy, phenoxy, linking group, and substituted forms thereof. The invention further includes energy transfer dyes comprising the dibenzorhodamine compounds, nucleosides labeled with the dibenzorhodamine compounds, and nucleic acid analysis methods employing the dibenzorhodamine compounds.

  本发明公开了具有结构1的二苯基罗丹明化合物，包括其氮代和芳基取代形式。此外，还公开了用于合成这种化合物的两种中间体，第一中间体具有结构2，包括其氮代和芳基取代形式，第二中间体具有结构3，包括其氮代和芳基取代形式，其中在C-14到C18位置的取代基单独选择自氢、氯、氟、低碳基、羧酸、磺酸、—CH2OH、烷氧基、苯氧基、连接基和其取代形式的群。本发明还包括包含二苯基罗丹明化合物的能量转移染料，使用二苯基罗丹明化合物标记的核苷酸和使用二苯基罗丹明化合物的核酸分析方法。
• A1 adenosine receptor antagonists
  申请人：Zablocki Jeff

  公开号：US20050059683A1

  公开（公告）日：2005-03-17

  Disclosed are novel methods of antagonizing the A 1 adenosine receptor in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the formula: wherein R 1 is optionally substituted C 1-4 alkyl; Y is C 1-4 alkylene; and Z is phenyl that is optionally substituted with halo, hydroxy, amino, cyano, or optionally substituted C 1-4 alkyl or a pharmaceutically acceptable salt, ester, or prodrug thereof. The A 1 adenosine receptors are antagonized in order to treat a disease state is chosen from renal failure, renal dysfunction, nephritis, hypertension, oedema, Alzheimers disease, stress, depression, cardiac arrhythmia, restoration of cardiac function, congestive heart failure, diabetes, asthma, respiratory disorders, ischaemia-induced injury of the brain, heart and kidney, and diarrhea.

  所公开的是拮抗 A 1 腺苷受体的新方法，包括向有需要的哺乳动物施用治疗有效剂量的式化合物： 其中 R 1 是任选取代的 C 1-4 烷基 1-4 烯基；Z 是被卤代、羟基、氨基、氰基或任选取代的 C 1-4 烷基或其药学上可接受的盐、酯或原药。 A 1 腺苷受体被拮抗以治疗的疾病状态选自肾衰竭、肾功能不全、肾炎、高血压、水肿、老年痴呆症、应激、抑郁、心律失常、心功能恢复、充血性心力衰竭、糖尿病、哮喘、呼吸系统疾病、缺血引起的脑、心、肾损伤和腹泻。
• PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1401837B1

  公开（公告）日：2005-10-19